Barclays PLC Sesen Bio, Inc. Transaction History

Barclays PLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.38 - $0.89 $12,418 - $29,085	-32,680 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.58 - $0.86 $122,768 - $182,035	-211,669 Reduced 86.63%	32,680 $19,000
Q4 2021 Feb 14, 2022	BUY	$0.73 - $1.28 $117,608 - $206,218	161,108 Added 193.54%	244,349 $199,000
Q3 2021 Nov 09, 2021	BUY	$0.77 - $4.91 $45,461 - $289,891	59,041 Added 243.97%	83,241 $66,000
Q2 2021 Aug 13, 2021	SELL	$2.18 - $4.66 $275,647 - $589,229	-126,444 Reduced 83.94%	24,200 $112,000
Q1 2021 May 13, 2021	BUY	$1.3 - $3.24 $195,837 - $488,086	150,644 New	150,644 $392,000
Q1 2020 May 13, 2020	SELL	$0.39 - $1.03 $0 - $1	-1 Closed	0 $0
Q4 2019 Feb 10, 2020	BUY	$0.89 - $1.5 $0 - $1	1 New	1 $0
Q3 2019 Nov 14, 2019	SELL	$1.04 - $1.51 $206 - $300	-199 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$0.69 - $1.47 $137 - $292	199 New	199 $0
Q3 2018 Nov 14, 2018	SELL	$1.54 - $2.38 $49,742 - $76,874	-32,300 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$1.04 - $3.29 $33,592 - $106,267	32,300 New	32,300 $63,000

Ticker SESN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,702,000
Market Cap $127M
Description
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.